Table 1.

Pilot dosing study—8 weeks ad libitum consumption

Control0.025%EPA+DHA0.05%EPA+DHA
dietdietdiet
For erythrocytesn = 4n = 5n = 5
For serumn = 5n = 6n = 7
Erythrocyte EPA0.19 ± 0.01a2.53 ± 0.28b1.41 ± 0.11b
Serum EPA0.16 ± 0.02a1.66 ± 0.09b1.05 ± 0.08b
Erythrocyte DHA5.59 ± 0.52a7.86 ± 0.907.99 ± 0.81b
Serum DHA5.01 ± 0.385.13 ± 0.175.51 ± 0.32
Erythrocyte AA14.5 ± 1.01a9.06 ± 0.92b10.5 ± 0.80b
Serum AA11.6 ± 0.91a5.47 ± 0.58b7.59 ± 0.51b
Erythrocyte (EPA + DHA):AA0.40 ± 0.01a1.16 ± 0.09b0.89 ± 0.03b
Serum (EPA + DHA):AA0.45 ± 0.01a1.31 ± 0.15b0.88 ± 0.05b
Erythrocyte n-3: n-60.25 ± 0.01a0.60 ± 0.04b0.52 ± 0.02b
Serum n-3: n-60.31 ± 0.01a0.52 ± 0.06b0.43 ± 0.02b

NOTE: Erythrocyte (percentage of total phospholipid) and serum (percentage of total cholesterol ester and phospholipid) levels of EP, DH, AA, the ratio of EPA + DHA: AA, and the ratio of n-3: n-6 fatty acids. Statistically significant (P ≤ 0.05) differences are indicated by different letters, e.g., a group designated with a is different than a group designated with b; but two groups with b are not different.